{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:04:47Z","timestamp":1759017887822,"version":"3.44.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 GM007750"],"award-info":[{"award-number":["T32 GM007750"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clinthera.2021.08.016","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T14:35:30Z","timestamp":1632494130000},"page":"2032-2039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Analysis of Drug-Drug Interaction Labeling Language and Clinical Recommendations for Newly Approved Drugs Evaluated With Digoxin, Midazolam, and S-Warfarin"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9444-4064","authenticated-orcid":false,"given":"Lindsay M.","family":"Henderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-4020","authenticated-orcid":false,"given":"Claire E.","family":"Steinbronn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine K.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4591-6162","authenticated-orcid":false,"given":"Isabelle","family":"Ragueneau-Majlessi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.08.016_bib0001","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.xphs.2017.04.016","article-title":"Clinical drug\u2013drug interaction evaluations to inform drug use and enable drug access","volume":"106","author":"Reki\u0107","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2021.08.016_bib0002","first-page":"1","article-title":"In Vitro Drug Interaction Studies - Cytochrome P450 Enzyme and Transporter Mediated Drug Interactions","volume":"1","author":"FDA","year":"2020","journal-title":"FDA Guid"},{"key":"10.1016\/j.clinthera.2021.08.016_bib0004","unstructured":"Drug Development and Drug Interactions Table: Substrates, Inhibitors, and Inducers @ fda.gov. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table3-2"},{"key":"10.1016\/j.clinthera.2021.08.016_bib0005","first-page":"1","article-title":"Clinical pharmacology section of labeling for human prescription drug and biological products - content","volume":"2016","author":"US Food and Drug","year":"2016","journal-title":"and format"},{"journal-title":"Published online","article-title":"Guidance for Industry Statistical Approaches to Establishing Bioequivalence","year":"2001","key":"10.1016\/j.clinthera.2021.08.016_bib0006"},{"key":"10.1016\/j.clinthera.2021.08.016_bib0007","unstructured":"Novartis. TABRECTA (capmatinib) [product label]. Published online 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213591s000lbl.pdf"},{"key":"10.1016\/j.clinthera.2021.08.016_bib0008","unstructured":"AbbVie. MAVYRET (glecaprevir and pibrentasvir) [product label]. Published online 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209394s010lbl.pdf"},{"author":"Facts","key":"10.1016\/j.clinthera.2021.08.016_bib0009"},{"key":"10.1016\/j.clinthera.2021.08.016_bib0010","unstructured":"UpToDate. https:\/\/www.uptodate.com\/contents\/search"},{"key":"10.1016\/j.clinthera.2021.08.016_bib0011","unstructured":"Micromedex. https:\/\/www.micromedexsolutions.com\/home\/dispatch\/ssl\/true"},{"key":"10.1016\/j.clinthera.2021.08.016_bib0012","unstructured":"Novartis. KISQALI (ribociclib) [product label]. Published online 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209092s005lbl.pdf"},{"key":"10.1016\/j.clinthera.2021.08.016_bib0013","unstructured":"Gilead. ZYDELIG (idelalisib) [product label]. Published online 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/205858s014lbl.pdf"},{"key":"10.1016\/j.clinthera.2021.08.016_bib0014","unstructured":"Boehringer Ingelheim. JARDIANCE (empagliflozin) [product label]. Published online 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/204629s023lbl.pdf"},{"key":"10.1016\/j.clinthera.2021.08.016_bib0015","unstructured":"Merck. PREVYMIS (letermovir) [product label]. Published online 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209939s008,209940s006lbl.pdf"},{"key":"10.1016\/j.clinthera.2021.08.016_bib0016","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.2010.271","article-title":"Rifampin\u2019s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug\u2013drug interaction trial design","volume":"89","author":"Reitman","year":"2011","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821003155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821003155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:56:20Z","timestamp":1758963380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821003155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0149291821003155"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.08.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of Drug-Drug Interaction Labeling Language and Clinical Recommendations for Newly Approved Drugs Evaluated With Digoxin, Midazolam, and S-Warfarin","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}